Integral Health Asset Management’s Neurocrine Biosciences NBIX Stock Holding History

Integral Health Asset Management’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$25.3M	Hold	150,000	–	–	1%	29
2026 Q1	$19.8M	Hold	150,000	–	–	0.95%	26
2025 Q4	$21.3M	Hold	150,000	–	–	1.06%	32
2025 Q3	$21.1M	Hold	150,000	–	–	1.42%	21
2025 Q2	$18.9M	Hold	150,000	–	–	1.73%	17
2025 Q1	$16.6M	Sell	150,000 -10,000	-6%	-$1.27M	1.77%	14
2024 Q4	$21.8M	Buy	+160,000	New	+$19.8M	1.86%	14
2024 Q3	–	Sell	-70,000	Closed	-$9.64M	–	89
2024 Q2	$9.64M	Sell	70,000 -80,000	-53%	-$11M	0.92%	37
2024 Q1	$20.7M	Buy	150,000 +60,000	+67%	+$8.19M	1.92%	17
2023 Q4	$11.9M	Buy	90,000 +5,000	+6%	+$576K	1.62%	24
2023 Q3	$9.56M	Buy	+85,000	New	+$8.95M	1.32%	29
2022 Q4	–	Sell	-90,000	Closed	-$9.56M	–	84
2022 Q3	$9.56M	Buy	+90,000	New	+$9.13M	1.86%	20
2022 Q2	–	Sell	-35,000	Closed	-$3.28M	–	79
2022 Q1	$3.28M	Buy	+35,000	New	+$2.97M	0.85%	42
2020 Q3	–	Sell	-20,000	Closed	-$2.44M	–	84
2020 Q2	$2.44M	Buy	+20,000	New	+$2.21M	0.73%	49
2020 Q1	–	Sell	-15,000	Closed	-$1.61M	–	69
2019 Q4	$1.61M	Buy	+15,000	New	+$1.57M	0.63%	43

Other funds holding NBIX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Integral Health Asset Management's NBIX Position: Q2 2026 in Review

Integral Health Asset Management held its Neurocrine Biosciences (NBIX) position steady in Q2 2026 at 150,000 shares worth $25.3M. The position accounts for 1% of the portfolio, ranked #29.

Integral Health Asset Management first reported a position in NBIX in Q4 2019 and has held it in 15 quarters since. 775 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

Integral Health Asset Management held 150,000 shares of Neurocrine Biosciences worth $25.3M as of Q2 2026.
Integral Health Asset Management left its Neurocrine Biosciences share count unchanged in Q2 2026.
Neurocrine Biosciences made up 1% of Integral Health Asset Management's portfolio in Q2 2026, its #29 holding.
Integral Health Asset Management first reported a position in Neurocrine Biosciences in Q4 2019 and has held it in 15 quarters since.
775 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Integral Health Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.